Isoniazid is a first-line medicine for tuberculosis (TB) treatment. It is a prodrug activated by the mycobacterial catalase-peroxidase enzyme KatG. However, the development of isoniazid resistance compromises treatment efficacy and contributes to multidrug-resistant TB infections.